Advertisement

Latency of Symptom Progression in Mild Daboia palaestinae Envenomation

Published:April 21, 2022DOI:https://doi.org/10.1016/j.wem.2022.03.004

      Introduction

      Daboia palestinae is the most common venomous snake in Israel. In most cases, snakebite does not develop into a systemic disease. Since the introduction of specific antivenom therapy, the mortality rate has declined sharply. Nevertheless, there is still no uniform therapeutic protocol in Israel for patients who have been envenomated, and there is no current data regarding latency of symptom development. We aimed to evaluate the latency of symptom development after D palaestinae snakebite in patients presenting to the emergency department (ED) with local reaction.

      Methods

      This was a retrospective single-center study of all patients who presented following a snakebite from 2015 to 2020. Patients with confirmed or suspected D palaestinae bite were included. Demographical and clinical data were extracted from each electronical medical record and subjected to descriptive and comparative analysis.

      Results

      Sixty-two patients met the inclusion criteria. Their median (IQR) age was 30 (17–48) y, and 75% were male. Forty-one percent presented with local reactions to the snakebite, 29% presented with advanced local reaction, and 29% presented with systemic symptoms. Antivenom was given to 22% of patients with advanced local reaction and 89% of patients with systemic reaction. The median (IQR) time from bite to antivenom and from ED arrival to antivenom were 2 (1.5–2.5) h and 1 (0.75–1.5) h, respectively. Antivenom was administered at the latest 3.5 h after presentation to the ED for progression of local symptoms.

      Conclusions

      Our study may support a 4- to 6-h observation period in the ED for patients with mild clinical presentation after D palaestinae bite. Further larger prospective studies are needed.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Wilderness & Environmental Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kochva E.
        Venomous snakes of Israel: ecology and snakebite.
        Public Health Rev. 1998; 26: 209-232
        • Paret G.
        • Ben Abraham R.
        • Ezra D.
        • Shrem D.
        • Eshel G.
        • Vardi A.
        • et al.
        Vipera palaestinae snake envenomations: experience in children.
        Hum Exp Toxicol. 1997; 16: 683-687
        • Momic T.
        • Arlinghaus F.T.
        • Arien-Zakay H.
        • Katzhendler J.
        • Eble J.A.
        • Marcinkiewicz C.
        • et al.
        Pharmacological aspects of Vipera xantina palestinae venom.
        Toxins (Basel). 2011; 3: 1420-1432
        • Wang A.H.
        • Gordon D.
        • Drescher M.J.
        • Shiber S.
        Is there a benefit for administration of antivenom following local and mild systemic reactions to Daboia (Vipera) palaestinae snake bites?.
        Toxin Rev. 2018; 39: 52-56
        • Winkler E.
        • Chovers M.
        • Almog S.
        • Gopalakrishnakone P.
        • Tan C.K.V.
        Palestinae bites-clinical experience in Israel.
        Recent Adv Toxicol Res. 1992; 1: 329-336
        • Abraham R.B.
        • Winkler E.
        • Eshel G.
        • Barzilay Z.
        • Paret G.
        Snakebite poisoning in children--a call for unified clinical guidelines.
        Eur J Emerg Med. 2001; 8: 189-192
        • Pivko-Levy D.
        • Munchnak I.
        • Rimon A.
        • Balla U.
        • Scolnik D.
        • Hoyte C.
        • et al.
        Evaluation of antivenom therapy for Vipera palaestinae bites in children: experience of two large, tertiary care pediatric hospitals.
        Clin Toxicol (Phila). 2017; 55: 235-240
        • Shemesh I.Y.
        • Kristal C.
        • Langerman L.
        • Bourvin A.
        Preliminary evaluation of Vipera palaestinae snake bite treatment in accordance to the severity of the clinical syndrome.
        Toxicon. 1998; 36: 867-873
        • Bentur Y.
        • Cahana A.
        Unusual local complications of Vipera palaestinae bite.
        Toxicon. 2003; 41: 633-635
        • Le Geyt J.
        • Pach S.
        • Gutierrez J.M.
        • Habib A.G.
        • Maduwage K.P.
        • Hardcastle T.C.
        • et al.
        Paediatric snakebite envenoming: recognition and management of cases.
        Arch Dis Child. 2021; 106: 14-19
        • Warrell D.
        Guidelines for the management of snakebites, 2nd edition. 2016.
        (Available at:) (Accessed August 22, 2021)
        • Lopoo J.B.
        • Bealer J.F.
        • Mantor P.C.
        • Tuggle D.W.
        Treating the snakebitten child in North America: a study of pit viper bites.
        J Pediatr Surg. 1998; 33: 1593-1595
        • Blackman J.R.
        • Dillon S.
        Venomous snakebite: past, present, and future treatment options.
        J Am Board Fam Pract. 1992; 5: 399-405
        • Bentur Y.
        • Zveibel F.
        • Adler M.
        • Raikhlin B.
        Delayed administration of Vipera xanthina palaestinae antivenin.
        J Toxicol Clin Toxicol. 1997; 35: 257-261